TY - JOUR
T1 - Antiproliferative effect induced by novel imidazoline S43126 in PC12 cells is mediated by ROS, stress activated MAPKs and caspases
AU - McLean, Lancelot S.
AU - Crane, Louis
AU - Baziard-Mouysset, Genevieve
AU - Edwards, Lincoln P.
N1 - Copyright © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
PY - 2014/12
Y1 - 2014/12
N2 - Background Some imidazoline compounds have pleiotropic effects including cell death in vitro. We examined the antiproliferative action of a novel imidazoline compound S43126, and the role of the I1-imidazoline receptor, ROS, MAPKs and caspases in S43126-induced cell death. Methods PC 12 cells were treated with various concentrations of S43126 in the presence or absence of several ligands, and the effects on cell proliferation, ROS levels, and apoptosis were evaluated using Trypan Blue, Alamar Blue, Western blot and microscopy. Results We showed that S43126 reduced PC12 cell proliferation by greater than 50%, increased cell death by greater than 40% and increased apoptotic body formation. These effects were reversed by I1R- antagonist, efaroxan. S43126 also increased intracellular ROS levels by greater than 2.5-fold relative to vehicle-treated control. These effects were significantly inhibited by N-acetyl-cysteine. In addition, pharmacologic inhibitors of ERK, JNK and p38 MAPK, significantly reduced S43126-induced antiproliferative activity. Caspases 3, 8 and 9 were all activated in a time-dependent manner by S43126. Pan caspase inhibitor z-VAD-fmk, ameliorated the effects of S43126 on cell death and cell proliferation. Conclusion Our data showed that the effects of S43126 on PC12 cell death were partly mediated by ROS production, MAPK and caspase activation. These results further indicate an emerging role for I1R in apoptotic processes. © 2014 Institute of Pharmacology, Polish Academy of Sciences.
AB - Background Some imidazoline compounds have pleiotropic effects including cell death in vitro. We examined the antiproliferative action of a novel imidazoline compound S43126, and the role of the I1-imidazoline receptor, ROS, MAPKs and caspases in S43126-induced cell death. Methods PC 12 cells were treated with various concentrations of S43126 in the presence or absence of several ligands, and the effects on cell proliferation, ROS levels, and apoptosis were evaluated using Trypan Blue, Alamar Blue, Western blot and microscopy. Results We showed that S43126 reduced PC12 cell proliferation by greater than 50%, increased cell death by greater than 40% and increased apoptotic body formation. These effects were reversed by I1R- antagonist, efaroxan. S43126 also increased intracellular ROS levels by greater than 2.5-fold relative to vehicle-treated control. These effects were significantly inhibited by N-acetyl-cysteine. In addition, pharmacologic inhibitors of ERK, JNK and p38 MAPK, significantly reduced S43126-induced antiproliferative activity. Caspases 3, 8 and 9 were all activated in a time-dependent manner by S43126. Pan caspase inhibitor z-VAD-fmk, ameliorated the effects of S43126 on cell death and cell proliferation. Conclusion Our data showed that the effects of S43126 on PC12 cell death were partly mediated by ROS production, MAPK and caspase activation. These results further indicate an emerging role for I1R in apoptotic processes. © 2014 Institute of Pharmacology, Polish Academy of Sciences.
KW - Caspase
KW - Cell death
KW - Imidazoline
KW - Mitogen activated protein kinase
KW - Reactive oxygen species
KW - Reactive Oxygen Species/metabolism
KW - JNK Mitogen-Activated Protein Kinases/metabolism
KW - Apoptosis/drug effects
KW - Rats
KW - PC12 Cells
KW - Caspases/metabolism
KW - Dose-Response Relationship, Drug
KW - Animals
KW - Anisoles/administration & dosage
KW - Time Factors
KW - Imidazolines/administration & dosage
KW - Mitogen-Activated Protein Kinases/metabolism
KW - Cell Proliferation/drug effects
KW - Imidazoline Receptors/metabolism
UR - https://www.scopus.com/pages/publications/84905668383
UR - https://www.scopus.com/pages/publications/84905668383#tab=citedBy
UR - https://www.mendeley.com/catalogue/811695ec-321d-3a88-85ab-0bc7d423022b/
U2 - 10.1016/j.pharep.2014.06.003
DO - 10.1016/j.pharep.2014.06.003
M3 - Article
C2 - 25443718
SN - 2299-5684
VL - 66
SP - 937
EP - 945
JO - Pharmacological Reports
JF - Pharmacological Reports
IS - 6
ER -